aspirin has been researched along with Placenta Diseases in 21 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Placenta Diseases: Pathological processes or abnormal functions of the PLACENTA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To establish the clinical heterogeneity among the clinical practice guidelines (CPGs) on aspirin use in pregnancy and to investigate the quality of these CPGs." | 9.41 | Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review. ( Alameddine, S; D'Antonio, F; Di Girolamo, R; Khalil, A; Liberati, M; Maruotti, GM; Rizzo, G; Santilli, F, 2023) |
| "To assess the effect of aspirin use in low-risk pregnancy on: (1) pregnancy-associated plasma protein-A (PAPP-A) and placental-like growth factor (PLGF); (2) urinary albumin-to-creatinine ratio (ACR) and blood pressure; (3) fetal growth parameters; and (4) placental histopathology." | 9.30 | Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT. ( Clarke, P; Culliton, M; Downey, P; Fitzgerald, D; Maguire, OC; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Mooney, EE; Mulcahy, C; Tully, E, 2019) |
| "A randomized, placebo-controlled, double-blind trial was carried out to evaluate the fetal benefits of low-dose aspirin (150 mg/day) as a treatment of placental insufficiency during the last trimester of pregnancy." | 9.06 | Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. ( Connelly, A; Cook, CM; Giles, WB; Thompson, RS; Trudinger, BJ, 1988) |
| "In this retrospective observational study including women with pre-existing hypertension, pre-gestational diabetes or previous placental-mediated complications, we compared the rates of pre-eclampsia, early-onset and severe pre-eclampsia between women who used 81 mg of aspirin (ASA) throughout pregnancy without platelet function analyser (PFA-100®) monitoring ("group ASA no PFA") and those in whom the aspirin dosage was adjusted according to PFA-100® results ("group ASA and PFA")." | 7.77 | Is testing for aspirin response worthwhile in high-risk pregnancy? ( Rey, E; Rivard, GE, 2011) |
| "Live birth rates are increased by treatment with heparin and aspirin in cases of poor pregnancy outcome such as antiphospholipid syndrome." | 7.73 | Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. ( Black, S; Bose, P; Huppertz, B; Kadyrov, M; Neulen, J; Regan, L; Weissenborn, U, 2005) |
| "Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide." | 6.53 | Aspirin vs Heparin for the Prevention of Preeclampsia. ( Kanellopoulou, T; Katsi, V; Makris, T; Nihoyannopoulos, P; Nomikou, E; Tousoulis, D, 2016) |
| "Reportedly, aspirin prevents preeclampsia, specifically early-onset preeclampsia, although findings in decidual arteries in women treated with aspirin therapy remain unclear." | 5.72 | Low-dose aspirin therapy improves decidual arteriopathy in pregnant women with a history of preeclampsia. ( Gi, T; Katsuragi, S; Kodama, Y; Maekawa, K; Sameshima, H; Sato, Y; Tomimori-Gi, K; Yamada, N; Yamashita, A, 2022) |
| "To establish the clinical heterogeneity among the clinical practice guidelines (CPGs) on aspirin use in pregnancy and to investigate the quality of these CPGs." | 5.41 | Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review. ( Alameddine, S; D'Antonio, F; Di Girolamo, R; Khalil, A; Liberati, M; Maruotti, GM; Rizzo, G; Santilli, F, 2023) |
| "To assess the effect of aspirin use in low-risk pregnancy on: (1) pregnancy-associated plasma protein-A (PAPP-A) and placental-like growth factor (PLGF); (2) urinary albumin-to-creatinine ratio (ACR) and blood pressure; (3) fetal growth parameters; and (4) placental histopathology." | 5.30 | Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT. ( Clarke, P; Culliton, M; Downey, P; Fitzgerald, D; Maguire, OC; Malone, FD; McAuliffe, FM; McParland, P; Mone, F; Mooney, EE; Mulcahy, C; Tully, E, 2019) |
| "A randomized, placebo-controlled, double-blind trial was carried out to evaluate the fetal benefits of low-dose aspirin (150 mg/day) as a treatment of placental insufficiency during the last trimester of pregnancy." | 5.06 | Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. ( Connelly, A; Cook, CM; Giles, WB; Thompson, RS; Trudinger, BJ, 1988) |
| "The use of aspirin and heparin has improved the pregnancy outcome in obstetric APS and approximately 70% of pregnant women with APS have a successful pregnancy outcome." | 4.95 | Current insights in obstetric antiphospholipid syndrome. ( Radin, M; Schreiber, K; Sciascia, S, 2017) |
| "In this retrospective observational study including women with pre-existing hypertension, pre-gestational diabetes or previous placental-mediated complications, we compared the rates of pre-eclampsia, early-onset and severe pre-eclampsia between women who used 81 mg of aspirin (ASA) throughout pregnancy without platelet function analyser (PFA-100®) monitoring ("group ASA no PFA") and those in whom the aspirin dosage was adjusted according to PFA-100® results ("group ASA and PFA")." | 3.77 | Is testing for aspirin response worthwhile in high-risk pregnancy? ( Rey, E; Rivard, GE, 2011) |
| "Live birth rates are increased by treatment with heparin and aspirin in cases of poor pregnancy outcome such as antiphospholipid syndrome." | 3.73 | Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. ( Black, S; Bose, P; Huppertz, B; Kadyrov, M; Neulen, J; Regan, L; Weissenborn, U, 2005) |
| "We report the cases of two patients who had a favorable outcome with aspirin and corticosteroid therapy during pregnancy for chronic villitis of unknown etiology complicated by labor asphyxia and further intrauterine fetal demise in one gravida 3 patient and for chronic intervillositis of unknown etiology diagnosed after three perinatal deaths in another patient (gravida 4)." | 3.73 | [Combining corticosteroid and aspirin for the prevention of recurrent villitis or intervillositis of unknown etiology]. ( Alnoukari, F; Barrier, J; Boog, G; Jossic, F; Le Vaillant, C; Muller, JY, 2006) |
| "Preeclampsia is a hypertensive disorder of pregnancy that remains a significant cause of maternal morbidity and mortality worldwide." | 2.53 | Aspirin vs Heparin for the Prevention of Preeclampsia. ( Kanellopoulou, T; Katsi, V; Makris, T; Nihoyannopoulos, P; Nomikou, E; Tousoulis, D, 2016) |
| "Preeclampsia, intrauterine growth restriction (IUGR), and placental abruption are obstetrical conditions that constitute the syndrome of ischemic placental disease or IPD, the leading cause of indicated preterm birth and an important cause of neonatal morbidity and mortality." | 2.50 | Prediction and prevention of ischemic placental disease. ( Cleary, KL; Friedman, AM, 2014) |
| "Reportedly, aspirin prevents preeclampsia, specifically early-onset preeclampsia, although findings in decidual arteries in women treated with aspirin therapy remain unclear." | 1.72 | Low-dose aspirin therapy improves decidual arteriopathy in pregnant women with a history of preeclampsia. ( Gi, T; Katsuragi, S; Kodama, Y; Maekawa, K; Sameshima, H; Sato, Y; Tomimori-Gi, K; Yamada, N; Yamashita, A, 2022) |
| " It is likely that proper selection of patients, as well as the timing and dosage of treatment, are key factors for its efficiency." | 1.30 | [Arterial hypertension of the pregnant woman]. ( Beaufils, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 10 (47.62) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Tomimori-Gi, K | 1 |
| Katsuragi, S | 1 |
| Kodama, Y | 1 |
| Yamada, N | 1 |
| Sameshima, H | 1 |
| Maekawa, K | 1 |
| Yamashita, A | 1 |
| Gi, T | 1 |
| Sato, Y | 1 |
| Di Girolamo, R | 1 |
| Alameddine, S | 1 |
| Khalil, A | 1 |
| Santilli, F | 1 |
| Rizzo, G | 1 |
| Maruotti, GM | 1 |
| Liberati, M | 1 |
| D'Antonio, F | 1 |
| Abdulghani, S | 1 |
| Moretti, F | 1 |
| Gruslin, A | 1 |
| Grynspan, D | 1 |
| Schreiber, K | 1 |
| Radin, M | 1 |
| Sciascia, S | 1 |
| Mone, F | 1 |
| Mulcahy, C | 1 |
| McParland, P | 1 |
| Downey, P | 1 |
| Culliton, M | 1 |
| Maguire, OC | 1 |
| Mooney, EE | 1 |
| Clarke, P | 1 |
| Fitzgerald, D | 1 |
| Tully, E | 1 |
| Malone, FD | 1 |
| McAuliffe, FM | 1 |
| Dodd, JM | 1 |
| McLeod, A | 1 |
| Windrim, RC | 1 |
| Kingdom, J | 1 |
| Bujold, E | 1 |
| Roberge, S | 1 |
| Nicolaides, KH | 1 |
| Friedman, AM | 1 |
| Cleary, KL | 1 |
| Katsi, V | 1 |
| Kanellopoulou, T | 1 |
| Makris, T | 1 |
| Nihoyannopoulos, P | 1 |
| Nomikou, E | 1 |
| Tousoulis, D | 1 |
| Skeith, L | 1 |
| Rodger, M | 1 |
| Rey, E | 1 |
| Rivard, GE | 1 |
| Cuckle, H | 1 |
| von Dadelszen, P | 1 |
| Ghidini, A | 1 |
| Bose, P | 1 |
| Black, S | 1 |
| Kadyrov, M | 1 |
| Weissenborn, U | 1 |
| Neulen, J | 1 |
| Regan, L | 1 |
| Huppertz, B | 1 |
| Verspyck, E | 1 |
| Marpeau, L | 1 |
| Boog, G | 1 |
| Le Vaillant, C | 1 |
| Alnoukari, F | 1 |
| Jossic, F | 1 |
| Barrier, J | 1 |
| Muller, JY | 1 |
| Pardini, S | 1 |
| Dore, F | 1 |
| Murineddu, M | 1 |
| Bontigli, S | 1 |
| Longinotti, M | 1 |
| Grigliotti, B | 1 |
| Spano, B | 1 |
| Ngo, VU | 1 |
| Cynober, E | 1 |
| Kammoun, M | 1 |
| Bouzaghar, A | 1 |
| Saranti, L | 1 |
| Jeny, R | 1 |
| Beaufils, M | 1 |
| Trudinger, B | 1 |
| Cook, CM | 2 |
| Thompson, R | 1 |
| Giles, W | 1 |
| Connelly, A | 2 |
| Trudinger, BJ | 1 |
| Thompson, RS | 1 |
| Giles, WB | 1 |
| Köpernick, H | 1 |
| Mest, HJ | 1 |
| Schwarz, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Aspirin Versus Metformin in Pregnancies at High Risk of Preterm Preeclampsia: a 3-arm Randomized Controlled Trial[NCT05580523] | 3,000 participants (Anticipated) | Interventional | 2023-07-03 | Recruiting | |||
| A Randomized Trial of Transplacental Aspirin Therapy for Early Onset Fetal Growth[NCT04557475] | Phase 3 | 0 participants (Actual) | Interventional | 2022-06-11 | Withdrawn (stopped due to We are modifying this trial's protocol and will resubmit a new application at a later date.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for aspirin and Placenta Diseases
| Article | Year |
|---|---|
Clinical practice guidelines on the use of aspirin in pregnancy: Systematic review.
Topics: Aspirin; Female; Fetal Growth Retardation; Humans; Placenta; Placenta Diseases; Platelet Aggregation | 2023 |
Current insights in obstetric antiphospholipid syndrome.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2017 |
Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction.
Topics: Aspirin; Dipyridamole; Eclampsia; Female; Fibrinolytic Agents; Heparin; Humans; Infant; Infant, Low | 2013 |
Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation.
Topics: Aspirin; Dose-Response Relationship, Drug; Female; Humans; Placenta Diseases; Placentation; Pregnanc | 2014 |
Prediction and prevention of ischemic placental disease.
Topics: Abruptio Placentae; Anticoagulants; Ascorbic Acid; Aspirin; Calcium, Dietary; Dietary Supplements; F | 2014 |
Aspirin vs Heparin for the Prevention of Preeclampsia.
Topics: Aspirin; Female; Heparin; Humans; Hypertension; Placenta Diseases; Pre-Eclampsia; Pregnancy | 2016 |
Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: Is it time to put the needles away?
Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Placent | 2017 |
[Thrombophilias and vascular placental pathology. A survey of the literature].
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cohort Studies; | 2005 |
3 trials available for aspirin and Placenta Diseases
| Article | Year |
|---|---|
Evaluation of the Effect of Low-Dose Aspirin on Biochemical and Biophysical Biomarkers for Placental Disease in Low-Risk Pregnancy: Secondary Analysis of a Multicenter RCT.
Topics: Adult; Albuminuria; Aspirin; Biomarkers; Creatinine; Female; Fetal Development; Humans; Placenta; Pl | 2019 |
Low-dose aspirin improves fetal weight in umbilical placental insufficiency.
Topics: Aspirin; Female; Fetus; Humans; Placenta Diseases; Placental Insufficiency; Pregnancy | 1988 |
Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency.
Topics: Adult; Aspirin; Birth Weight; Blood Flow Velocity; Clinical Trials as Topic; Double-Blind Method; Fe | 1988 |
10 other studies available for aspirin and Placenta Diseases
| Article | Year |
|---|---|
Low-dose aspirin therapy improves decidual arteriopathy in pregnant women with a history of preeclampsia.
Topics: Aspirin; Female; Gestational Age; Humans; Infant; Placenta; Placenta Diseases; Pre-Eclampsia; Pregna | 2022 |
Recurrent Massive Perivillous Fibrin Deposition and Chronic Intervillositis Treated With Heparin and Intravenous Immunoglobulin: A Case Report.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Chorionic Villi; Daltepar | 2017 |
Is testing for aspirin response worthwhile in high-risk pregnancy?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Canada; Diabetes Complications; Dose-Respon | 2011 |
Current controversies in prenatal diagnosis 4: pregnancy complications due to placental vascular disease (pre-eclampsia, FGR): are we ready for prevention?
Topics: Aspirin; Calcium; Female; Fetal Growth Retardation; Gestational Age; Humans; Placenta; Placenta Dise | 2013 |
Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure.
Topics: Abortion, Habitual; Anticoagulants; Apoptosis; Aspirin; Cell Line; Dose-Response Relationship, Drug; | 2005 |
[Combining corticosteroid and aspirin for the prevention of recurrent villitis or intervillositis of unknown etiology].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chorionic Villi; D | 2006 |
Alpha 2b-interferon therapy and pregnancy--report of a case of essential thrombocythemia.
Topics: Adult; Aspirin; Female; Humans; Infant, Newborn; Infarction; Interferon alpha-2; Interferon-alpha; P | 1993 |
[Retroplacental hematoma and uterine Doppler scan].
Topics: Adult; Aspirin; Birth Weight; Blood Flow Velocity; Diagnosis, Differential; Diastole; Female; Hemato | 1993 |
[Arterial hypertension of the pregnant woman].
Topics: Aspirin; Diagnosis, Differential; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Placenta D | 1999 |
Pharmacological management of an impending placental insufficiency.
Topics: Aspirin; Epoprostenol; Female; Gestational Age; Humans; Microcirculation; Placenta Diseases; Placent | 1988 |